Oncolytic rhabdovirus
AssigneeTurnstone Limited Partnership
InventorsDavid F. Stojdl, John Bell
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
Claims5
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated oncolytic recombinant rhabdovirus encoding a G protein sequence selected from the group consisting of (i) the Isfahan virus G protein sequence as set forth in SEQ ID NO:
- 26, (ii) the Maraba virus G protein sequence as set forth in SEQ ID NO:
- 5, (iii) the Muir Springs virus G protein sequence as set forth in SEQ ID NO:
- 21, (iv) a G protein having an amino acid sequence at least 96% identical to SEQ ID NO:
- 26, (v) a G protein having an amino acid sequence at least 96% identical to SEQ ID NO:
- 5 and (vi) a G protein having an amino acid sequence at least 96% identical to SEQ ID NO:
- 21;
- the rhabdovirus further encoding M, P, N and L proteins from vesicular stomatitis virus (VSV).
A composition comprising an isolated oncolytic recombinant rhabdovirus encoding a G protein sequence selected from the group consisting of (i) the Isfahan virus G protein sequence as set forth in SEQ ID NO:
- 26, (ii) the Maraba virus G protein sequence as set forth in SEQ ID NO:
- 5, (iii) the Muir Springs virus G protein sequence as set forth in SEQ ID NO:
- 21, (iv) a G protein having an amino acid sequence at least 96% identical to SEQ ID NO:
- 26, (v) a G protein having an amino acid sequence at least 96% identical to SEQ ID NO:
- 5 and (vi) a G protein having an amino acid sequence at least 96% identical to SEQ ID NO:
- 21;
- the rhabdovirus further encoding M, P, N and L proteins from vesicular stomatitis virus (VSV).
Dependencies are inferred from the claim text.